CD8A and neoplasm: An inhibitory NK-cell receptor NKG2A is expressed in half of peripheral NK cells and a small fraction of CD8+ T cells, and was found to be another checkpoint inhibitor that suppresses NK-cell effector functions against tumor cells expressing mouse NKG2A ligand, Qa-1 [102].